---
up: 
down: 
related: 
tags: []
type:
  - "[[SUB.LO.C.PEX.ANZCA]]"
dg-publish: true
title: 13.2_MSKPharmacology
date created: Wednesday, March 5th 2025, 20:58:29
date modified: Tuesday, March 25th 2025, 16:09:22
---

## 13.2 Muscular System Pharmacology

This section covers the pharmacological agents that affect the muscular system, focusing on neuromuscular blocking agents, including their mechanism of action, pharmacokinetics, pharmacodynamics, adverse effects, and reversal agents.

### Learning Objectives

- [[ANZCA.13.2.1_BT_GS.1.36_Neuromuscular_Blocking_Agents_Mechanism_Pharmacokinetics]]
- [[ANZCA.13.2.2_BT_GS.1.37_Neuromuscular_Blocking_Agents_Pharmacological_Differences]]
- [[ANZCA.13.2.3_BT_GS.1.37a_Neuromuscular_Blockade_Onset_Offset_Muscle_Groups]]
- [[ANZCA.13.2.4_BT_GS.1.38_Neuromuscular_Blocking_Agents_Adverse_Effects]]
- [[ANZCA.13.2.5_BT_GS.1.39_Neuromuscular_Blockade_Reversal_Drugs_Pharmacology]]
- [[ANZCA.13.2.6_BT_GS.1.40_Anticholinesterase_Agents_Adverse_Effects]]
- [[ANZCA.13.2.7_BT_GS.1.47_Muscle_Relaxation_Indications_Anaesthesia]]
- [[ANZCA.13.2.8_BT_GS.1.56_Inadequate_Reversal_Neuromuscular_Blockade_Management]]
